Latest Breaking News On - Karen preble - Page 5 : vimarsana.com

Intercept Announces Two Analyses Demonstrating Improvement

Efficacy of OCA vs. placebo and external controls accepted as a late-breaker poster HEROES-US data to be presented in oral session on Sunday, November 6 .

United statesNareg sagherianKaren prebleKrisv kowdleyWashington state universityKomodo healthElsons floyd college of medicineLiver instituteGlobal corporate communicationsIntercept pharmaceuticals incLiver meetingAmerican associationLiver diseasesObeticholic acidExternal controlClinical outcomes

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNareg sagherianM michelle berreyKaren prebleKrisv kowdleyWashington state universityKomodo healthElsons floyd college of medicineResearch developmentLiver instituteGlobal corporate communicationsIntercept pharmaceuticals incLiver meetingAmerican associationLiver diseasesObeticholic acid

Intercept Announces New Data to be Presented in PBC, Liver Fibrosis due to NASH and Pipeline at AASLD The Liver Meeting® 2022

Data from Phase 3 REGENERATE study supporting positive benefit-risk profile of obeticholic acid in liver fibrosis due to NASH to be featured in late-breaker podium presentation Analysis. | October 31, 2022

United statesSangeeta sawhneyPiotr milkiewiczMuhammady sheikhJames wasonJerome boursierStephena harrisonM michelle berreyJing liKaren prebleAndrewl masonJennifer callahanPhilipn newsomeMarco carboneTracy mayneC fiorella murillo perez

Intercept Pharmaceuticals Announces Summary of Key Actions in Strategic Financial Repositioning

21.09.2022 - Outstanding debt reduced by 54% or $388.9 million and annual cash interest expense reduced by 58% or $13.6 million Company well-positioned to drive continued growth in PBC, progress NASH program, expand and advance pipeline MORRISTOWN, N.J., Sept. .

Nareg sagherianKaren prebleJerry dursoGlobal corporate communicationsIntercept pharmaceuticals incSale of international businessConvertible notes exchangeInternational businessConvertible notesChief executive officerExecutive directorGlobal investorGlobal corporate

Intercept Pharmaceuticals Announces Repurchase of

MORRISTOWN, N.J., Aug. 19, 2022 (GLOBE NEWSWIRE) Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on.

United statesNareg sagherianKaren prebleGlobal corporate communicationsIntercept pharmaceuticals incConvertible senior secured notesSecurities actAnnual reportQuarterly reportExecutive directorGlobal investor relationsNasdaq icptIntercept pharmaceuticals